Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Definitive chemoradiation with or without cetuximab for oesophageal cancer
ISRCTN47718479Phase 3Completed
- Sponsor
- Velindre University NHS Trust
- Start
- Feb 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of cetuximab, cisplatin and capecitabine in esophageal cancer and esophagogastric junction cancer (2 arms), sponsored by Velindre University NHS Trust. Primary endpoints: Treatment failure and Overall survival. Started Feb 2008; status: completed.
02
Drugs
cetuximabcisplatincapecitabine
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on ISRCTN47718479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN47718479.